These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12870480)
1. Initiative launched to develop drugs for neglected diseases. Frankish H Lancet; 2003 Jul; 362(9378):135. PubMed ID: 12870480 [No Abstract] [Full Text] [Related]
2. [Drugs for 'neglected diseases': a bitter pill]. Veeken H; Pécoul B Ned Tijdschr Geneeskd; 2000 Jun; 144(26):1253-6. PubMed ID: 10908954 [TBL] [Abstract][Full Text] [Related]
3. Drug donated for treatment of visceral leishmaniasis. Burki T Lancet Infect Dis; 2012 Feb; 12(2):106-7. PubMed ID: 22389914 [No Abstract] [Full Text] [Related]
4. Leishmaniasis and Chagas Disease - Neglected Tropical Diseases: Treatment Updates. Sangenito LS; da Silva Santos V; d'Avila-Levy CM; Branquinha MH; Souza Dos Santos AL; de Oliveira SSC Curr Top Med Chem; 2019; 19(3):174-177. PubMed ID: 30950334 [No Abstract] [Full Text] [Related]
5. [Poor patients do not make a market]. Holen Ø Tidsskr Nor Laegeforen; 2004 Dec; 124(24):3226-8. PubMed ID: 15608773 [No Abstract] [Full Text] [Related]
8. Availability of miltefosine for the treatment of kala-azar in India. Sundar S; Murray HW Bull World Health Organ; 2005 May; 83(5):394-5. PubMed ID: 15976883 [No Abstract] [Full Text] [Related]
9. Visceral leishmaniasis: can we dream its eradication? Rege NN J Assoc Physicians India; 2001 Jun; 49():605-8. PubMed ID: 11584933 [No Abstract] [Full Text] [Related]
10. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513 [TBL] [Abstract][Full Text] [Related]
11. Treatment options for visceral leishmaniasis. den Boer M; Davidson RN Expert Rev Anti Infect Ther; 2006 Apr; 4(2):187-97. PubMed ID: 16597201 [TBL] [Abstract][Full Text] [Related]
12. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Murray HW Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475 [No Abstract] [Full Text] [Related]
17. Antiprotozoal compounds: state of the art and new developments. Astelbauer F; Walochnik J Int J Antimicrob Agents; 2011 Aug; 38(2):118-24. PubMed ID: 21549569 [TBL] [Abstract][Full Text] [Related]
18. Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease. Cardona-G W; Yepes AF; Herrera-R A Curr Med Chem; 2018; 25(30):3637-3679. PubMed ID: 29521209 [TBL] [Abstract][Full Text] [Related]
19. US incentive scheme for neglected diseases: a good idea gone wrong? Doshi P BMJ; 2014 Jul; 349():g4665. PubMed ID: 25099712 [No Abstract] [Full Text] [Related]
20. Developments in the treatment of visceral leishmaniasis. den Boer ML; Alvar J; Davidson RN; Ritmeijer K; Balasegaram M Expert Opin Emerg Drugs; 2009 Sep; 14(3):395-410. PubMed ID: 19708817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]